Electrophysiologic Mechanisms of Ketamine Antidepressant Response
Trial statusNot yet recruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18+
SponsorEmory University
About this trial
This study aims to identify electrophysiologic biomarkers associated with antidepressant response to ketamine in adults with epilepsy undergoing clinically indicated stereo-electroencephalography (sEEG) monitoring who have at least mild depressive symptoms.
Participants will receive a single subanesthetic intravenous ketamine infusion (0.5 mg/kg over 40 minutes) during their Epilepsy Monitoring Unit admission. Intracranial neural recordings and behavioral assessments will be collected before and approximately 24 hours after infusion to examine changes in neural circuits associated with rumination and anhedonia.
Eligibility criteria
Qualifiers
Admitted to the Emory EMU for clinically indicated sEEG monitoring for epilepsy.
At least mild depressive symptoms at baseline, defined as MADRS ≥7 or BDI-II ≥14.
Electrode coverage that includes midline regions sufficient for enrollment and analyses.
Ability to provide informed consent and to complete bedside tasks/questionnaires in English.
Disqualifiers
Documented IQ <70, intellectual disability, severe cognitive impairment, delirium, severe aphasia, or other condition that prevents valid consent or task participation.
Current or past schizophrenia-spectrum disorder or other psychotic disorder.
Current manic/hypomanic episode or bipolar-spectrum illness judged by study psychiatrist/investigator to increase risk or confound interpretation.
Active alcohol or substance abuse/dependence within the past 3 months.
Trial design
Treatments tested in this trial
- Ketamine
Treatment groups
37 Participants
are divided into 1 treatment groupSponsors and collaborators
Emory University
Lead sponsor
National Institutes of Health (NIH)
Collaborator
Source ClinicalTrials.gov